Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Primary Care
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
Related Questions
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
For patients with modest hyperbilirubinemia (Tbili 2-3) due to chronic liver disease, but otherwise normal liver indices, would you consider still utilizing enfortumab vedotin for metastatic urothelial carcinoma?
In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
